Incannex Healthcare Inc.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing psychedelic and cannabinoid-based therapies, with a current focus on oral psilocybin candidate PSX-001 and other pipeline programs such as IHL-42X and IHL-675A. The company also operates patient-service clinics, including rehabilitation and psychedelic-assisted therapy services, while it advances drug candidates through clinical trials and regulatory review.

−27 375,6 %

−54 517,4 %

+616,7 %

2.86

2.86

— Incannex Healthcare Inc.
%
Clinical-stage drug development70% Pipeline programs advancing psychedelic and other therapeutic candidates through preclinical and clinical trials.
Patient services and clinics20% Rehabilitation and clinic-based services delivered to patients while the drug pipeline matures.
Psychedelic-assisted therapy commercialization5% Joint-venture clinic model supporting authorized prescribers and integrated therapy delivery.
Manufacturing and development services5% cGMP drug product development and manufacturing support for clinical supply.

Incannex's current paying customers are clinic patients using rehabilitation services, while its future commercial...

  • Clinic patientsprimary

    Patients purchasing rehabilitation and related clinic services from Clarion Clinics today.

  • Physicians and healthcare providersprimary

    Clinicians who would recommend or prescribe approved drug candidates and support adoption.

  • Third-party payorsprimary

    Insurers and health systems that determine reimbursement and access for future products.

  • Authorized prescribers and therapy clinicssecondary

    Practitioners and clinics participating in the MMA Clinics psychedelic-assisted therapy network.

Incannex is headquartered in Australia but is incorporated in Delaware and operates through subsidiaries in Australia...

  • •Head office currently in Norwest, New South Wales, Australia
  • •Delaware parent company with U.S. operating subsidiary
  • •Clinical trial activity in the United States and the United Kingdom
  • •Commercial and clinic operations in Australia
  • •Planned relocation of principal office to Dubai

The company's strategy is to advance a diversified pipeline while building near-term service revenue through clinics...

01
Initiate and execute PSX-001 Phase 2b trialshort-term

Clinical proof-of-concept is needed to support future regulatory and commercial value.

02
Reallocate capital toward U.S. development opportunitiesshort-term

Management believes an expedited regulatory pathway may be available in the U.S. for some programs.

03
Scale clinic and JV commercialization modelmedium-term

Patient-service revenue can partially offset R&D burn while building a future treatment network.

04
Secure manufacturing and IP protectionmedium-term

Clinical supply and patent protection are essential to preserve pipeline economics.

Incannex remains a loss-making clinical-stage company with substantial dependence on external financing, trial...

critical

Clinical development failure or delay

Pipeline value depends on positive trial outcomes and timely regulatory progress.

Scope
PSX-001, IHL-42X, IHL-675A
Materiality
high
high

Liquidity and going-concern pressure

The company has a history of losses and limited current product revenue, so it relies on equity funding.

Scope
Corporate funding and R&D continuation
Materiality
high
high

Reimbursement and pricing uncertainty

Future commercialization depends on payor coverage and acceptable reimbursement rates.

Scope
Approved therapies and clinic services
Materiality
high
high

Intellectual property protection

Without patent coverage, competitors could replicate or commercialize similar therapies.

Scope
PSX-001 and related formulations
Materiality
high
medium

Foreign exchange and cross-border execution

Operations span Australia, the U.S., the U.K. and potentially Dubai, creating currency and compliance exposure.

Scope
International subsidiaries and trials
Materiality
medium
Revenue recognition for clinic services
Clarion Clinics and rehabilitation services
Research and development expense timing
PSX-001, IHL-42X, IHL-675A
Stock-based compensation
Corporate overhead and reported operating loss
Going-concern and liquidity assumptions
Disclosure risk and valuation

Inhibrx Biosciences, Inc.

INBX · Biological Products, (No Diagnostic Substances)

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

Enveric Biosciences, Inc.

ENVB · Pharmaceutical Preparations

Instil Bio, Inc.

TIL · Biological Products, (No Diagnostic Substances)

Pulmatrix, Inc.

PULM · Pharmaceutical Preparations

CANNAPHARMARX, INC.

CPMD · Pharmaceutical Preparations

: 28/04/2026